Dr. Thomas So Talks Diabetes & Obesity Drugs, Clinical Trials
By Tamara Thomas - Last Updated: October 13, 2023Thomas So, PharmD, a clinical pharmacist and Sr. Manager of Consumer Drug Information Group at FDB (First Databank), discusses diabetes and obesity drugs currently on the market and related clinical research.
Related Posts
“New ED diagnoses are associated with previously undiagnosed prediabetes and T2D."
Eye specialists are unsure when anti-VEGF treatment should start to achieve the best long-term outcome
An estimated 9.6 million people in the U.S. had diabetic-related eye disease – roughly 26% of diabetics.
Approximately 70% of new diagnoses of type 2 diabetes worldwide have been linked to poor diet.
Artificial sweeteners may be just as harmful as sugar as it accumulates in adipose tissue and may result in obesity.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.